- Author:
Sunghwan SUH
1
;
Kwang Won KIM
Author Information
- Publication Type:Review
- Keywords: Diabetes mellitus; Mass screening; Neoplasms
- MeSH: Breast; Diabetes Mellitus; Diabetes Mellitus, Type 2; Early Detection of Cancer; Gastrointestinal Neoplasms; Gonadal Steroid Hormones; Humans; Hyperglycemia; Hyperinsulinism; Incidence; Inflammation; Mass Screening; Mortality; Obesity; Oxidative Stress; Pancreas; Primary Prevention; Risk Factors; Smoke; Smoking
- From:Diabetes & Metabolism Journal 2019;43(6):733-743
- CountryRepublic of Korea
- Language:English
- Abstract: Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation. However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment.